Simon Boyd

Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

William HK Schilling, Podjanee Jittamala, James A Watson et al. · The Lancet Infectious Diseases · 2023 · 95 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial

Viravarn Luvira, William HK Schilling, Podjanee Jittamala et al. · BMC Infectious Diseases · 2024 · 29 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV)

Podjanee Jittamala, William HK Schilling, James A Watson et al. · The Journal of Infectious Diseases · 2023 · 28 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV)

William HK Schilling, Podjanee Jittamala, James A Watson et al. · eLife · 2023 · 20 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV)

Phrutsamon Wongnak, William HK Schilling, Podjanee Jittamala et al. · The Lancet Infectious Diseases · 2024 · 17 citations · Full text

Medicine, Infectious Diseases, Pharmacology +16